The estimated Net Worth of Reginald Seeto is at least $19.1 Milion dollars as of 2 October 2023. Reginald Seeto owns over 2,818 units of Caredx Inc stock worth over $13,670,549 and over the last 8 years he sold CDNA stock worth over $3,860,588. In addition, he makes $1,530,620 as President, Chief Executive Officer a Director at Caredx Inc.
Reginald has made over 31 trades of the Caredx Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 2,818 units of CDNA stock worth $19,472 on 2 October 2023.
The largest trade he's ever made was exercising 33,243 units of Caredx Inc stock on 25 June 2021 worth over $898,891. On average, Reginald trades about 3,392 units every 37 days since 2016. As of 2 October 2023 he still owns at least 479,164 units of Caredx Inc stock.
You can see the complete history of Reginald Seeto stock trades at the bottom of the page.
Dr. Reginald Seeto has been appointed as President, Chief Executive Officer, Director of the Company effective 11/1/2020. He has served as the Company’s President and Chief Business Officer since November 2018. Dr. Seeto served as the Chief Operating Officer of Ardelyx, Inc., a specialized biopharmaceutical company, from October 2016 through mid-August 2018 and continued with Ardelyx, Inc. from August 2018 through December 2018 as a consultant. From April 2008 until October 2016, Dr. Seeto held various positions of increasing responsibility at MedImmune Limited, a biotechnology company and subsidiary of AstraZeneca Plc, and at AstraZeneca, most recently serving as vice president, head of partnering and strategy for AstraZeneca. Earlier, he served as company president of AstraZeneca Thailand and before that, as executive vice president of corporate development and strategy for MedImmune. Prior to joining AstraZeneca/MedImmune, Dr. Seeto held senior marketing roles at Organon Biosciences, which was acquired by Schering Plough in 2007, and Boehringer Ingelheim Pharmaceuticals. Earlier, Dr. Seeto served as an engagement manager for McKinsey & Company and started his career as a practicing medical doctor and clinical researcher in Australia. Dr. Seeto earned both his BScMed (Hons) and MBBS (Hons) in medical studies from the University of Sydney, Australia.
As the President, Chief Executive Officer a Director of Caredx Inc, the total compensation of Reginald Seeto at Caredx Inc is $1,530,620. There are 2 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of $8,855,740.
Reginald Seeto is 49, he's been the President, Chief Executive Officer a Director of Caredx Inc since 2020. There are 9 older and 7 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
Reginald's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, 4TH FLOOR, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon a Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: